vs
FLOWSERVE CORP（FLS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FLOWSERVE CORP的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 7.6%，领先5.1%），Revvity同比增速更快（5.9% vs -6.7%），过去两年Revvity的营收复合增速更高（9.0% vs -3.9%）
Flowserve是美国跨国企业，也是全球领先的工业及环保机械供应商之一，主营泵、阀门、端面机械密封、自动化产品及相关服务，覆盖电力、油气、化工等多个行业，总部位于得克萨斯州欧文市，在全球50多国拥有近1.6万名员工，同时提供完善的售后服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FLS vs RVTY — 直观对比
营收规模更大
FLS
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出12.5%
-6.7%
净利率更高
RVTY
高出5.1%
7.6%
两年增速更快
RVTY
近两年复合增速
-3.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $81.7M | $98.4M |
| 毛利率 | 35.6% | — |
| 营业利润率 | 11.2% | 14.5% |
| 净利率 | 7.6% | 12.7% |
| 营收同比 | -6.7% | 5.9% |
| 净利润同比 | 10.5% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FLSRVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M |
净利润FLSRVTY
| Q1 26 | $81.7M | — | ||
| Q4 25 | $-29.0M | $98.4M | ||
| Q3 25 | $219.6M | $46.7M | ||
| Q2 25 | $81.8M | $53.9M | ||
| Q1 25 | $73.9M | $42.2M | ||
| Q4 24 | $77.5M | $94.6M | ||
| Q3 24 | $58.4M | $94.4M | ||
| Q2 24 | $72.6M | $55.4M |
毛利率FLSRVTY
| Q1 26 | 35.6% | — | ||
| Q4 25 | 34.8% | — | ||
| Q3 25 | 32.4% | 53.6% | ||
| Q2 25 | 34.2% | 54.5% | ||
| Q1 25 | 32.3% | 56.5% | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 31.5% | 56.3% | ||
| Q2 24 | 31.6% | 55.7% |
营业利润率FLSRVTY
| Q1 26 | 11.2% | — | ||
| Q4 25 | 3.5% | 14.5% | ||
| Q3 25 | 6.7% | 11.7% | ||
| Q2 25 | 12.3% | 12.6% | ||
| Q1 25 | 11.5% | 10.9% | ||
| Q4 24 | 10.6% | 16.3% | ||
| Q3 24 | 9.1% | 14.3% | ||
| Q2 24 | 10.5% | 12.4% |
净利率FLSRVTY
| Q1 26 | 7.6% | — | ||
| Q4 25 | -2.4% | 12.7% | ||
| Q3 25 | 18.7% | 6.7% | ||
| Q2 25 | 6.9% | 7.5% | ||
| Q1 25 | 6.5% | 6.4% | ||
| Q4 24 | 6.6% | 13.0% | ||
| Q3 24 | 5.2% | 13.8% | ||
| Q2 24 | 6.3% | 8.0% |
每股收益（稀释后）FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-0.21 | $0.86 | ||
| Q3 25 | $1.67 | $0.40 | ||
| Q2 25 | $0.62 | $0.46 | ||
| Q1 25 | $0.56 | $0.35 | ||
| Q4 24 | $0.59 | $0.77 | ||
| Q3 24 | $0.44 | $0.77 | ||
| Q2 24 | $0.55 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $792.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $7.3B |
| 总资产 | $5.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FLSRVTY
| Q1 26 | $792.4M | — | ||
| Q4 25 | $760.2M | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $675.4M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益FLSRVTY
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $2.3B | $7.4B | ||
| Q2 25 | $2.2B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B |
总资产FLSRVTY
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.7B | $12.2B | ||
| Q3 25 | $5.8B | $12.1B | ||
| Q2 25 | $5.7B | $12.4B | ||
| Q1 25 | $5.5B | $12.4B | ||
| Q4 24 | $5.5B | $12.4B | ||
| Q3 24 | $5.3B | $12.8B | ||
| Q2 24 | $5.2B | $13.4B |
负债/权益比FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-174.0K | $182.0M | ||
| Q3 25 | $401.8M | $138.5M | ||
| Q2 25 | $154.1M | $134.3M | ||
| Q1 25 | $-49.9M | $128.2M | ||
| Q4 24 | $197.3M | $174.2M | ||
| Q3 24 | $178.5M | $147.9M | ||
| Q2 24 | $-12.8M | $158.6M |
自由现金流FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-25.6M | $161.8M | ||
| Q3 25 | $384.7M | $120.0M | ||
| Q2 25 | $137.5M | $115.5M | ||
| Q1 25 | $-61.7M | $112.2M | ||
| Q4 24 | $168.5M | $149.8M | ||
| Q3 24 | $154.6M | $125.6M | ||
| Q2 24 | $-27.5M | $136.6M |
自由现金流率FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | -2.1% | 21.0% | ||
| Q3 25 | 32.8% | 17.2% | ||
| Q2 25 | 11.6% | 16.0% | ||
| Q1 25 | -5.4% | 16.9% | ||
| Q4 24 | 14.3% | 20.5% | ||
| Q3 24 | 13.6% | 18.4% | ||
| Q2 24 | -2.4% | 19.7% |
资本支出强度FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.0% | 2.4% | ||
| Q4 24 | 2.4% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 1.3% | 3.2% |
现金转化率FLSRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.83× | 2.97× | ||
| Q2 25 | 1.89× | 2.49× | ||
| Q1 25 | -0.68× | 3.03× | ||
| Q4 24 | 2.55× | 1.84× | ||
| Q3 24 | 3.06× | 1.57× | ||
| Q2 24 | -0.18× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FLS
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
